Cargando…

Advanced Materials for SARS‐CoV‐2 Vaccines

The ongoing coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute respiratory coronavirus 2 (SARS‐CoV‐2), has killed untold millions worldwide and has hurtled vaccines into the spotlight as a go‐to approach to mitigate it. Advances in virology, genomics, structural biology, and vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabrouk, Moustafa T., Huang, Wei‐Chiao, Martinez‐Sobrido, Luis, Lovell, Jonathan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957524/
https://www.ncbi.nlm.nih.gov/pubmed/34894000
http://dx.doi.org/10.1002/adma.202107781
_version_ 1784676776465661952
author Mabrouk, Moustafa T.
Huang, Wei‐Chiao
Martinez‐Sobrido, Luis
Lovell, Jonathan F.
author_facet Mabrouk, Moustafa T.
Huang, Wei‐Chiao
Martinez‐Sobrido, Luis
Lovell, Jonathan F.
author_sort Mabrouk, Moustafa T.
collection PubMed
description The ongoing coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute respiratory coronavirus 2 (SARS‐CoV‐2), has killed untold millions worldwide and has hurtled vaccines into the spotlight as a go‐to approach to mitigate it. Advances in virology, genomics, structural biology, and vaccine technologies have enabled a rapid and unprecedented rollout of COVID‐19 vaccines, although much of the developing world remains unvaccinated. Several new vaccine platforms have been developed or deployed against SARS‐CoV‐2, with most targeting the large viral Spike immunogen. Those that safely induce strong and durable antibody responses at low dosages are advantageous, as well are those that can be rapidly produced at a large scale. Virtually all COVID‐19 vaccines and adjuvants possess nanoscale or microscale dimensions and represent diverse and unique biomaterials. Viral vector vaccine platforms, lipid nanoparticle mRNA vaccines and multimeric display technologies for subunit vaccines have received much attention. Nanoscale vaccine adjuvants have also been used in combination with other vaccines. To deal with the ongoing pandemic, and to be ready for potential future ones, advanced vaccine technologies will continue to be developed in the near future. Herein, the recent use of advanced materials used for developing COVID‐19 vaccines is summarized.
format Online
Article
Text
id pubmed-8957524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89575242022-05-06 Advanced Materials for SARS‐CoV‐2 Vaccines Mabrouk, Moustafa T. Huang, Wei‐Chiao Martinez‐Sobrido, Luis Lovell, Jonathan F. Adv Mater Reviews The ongoing coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute respiratory coronavirus 2 (SARS‐CoV‐2), has killed untold millions worldwide and has hurtled vaccines into the spotlight as a go‐to approach to mitigate it. Advances in virology, genomics, structural biology, and vaccine technologies have enabled a rapid and unprecedented rollout of COVID‐19 vaccines, although much of the developing world remains unvaccinated. Several new vaccine platforms have been developed or deployed against SARS‐CoV‐2, with most targeting the large viral Spike immunogen. Those that safely induce strong and durable antibody responses at low dosages are advantageous, as well are those that can be rapidly produced at a large scale. Virtually all COVID‐19 vaccines and adjuvants possess nanoscale or microscale dimensions and represent diverse and unique biomaterials. Viral vector vaccine platforms, lipid nanoparticle mRNA vaccines and multimeric display technologies for subunit vaccines have received much attention. Nanoscale vaccine adjuvants have also been used in combination with other vaccines. To deal with the ongoing pandemic, and to be ready for potential future ones, advanced vaccine technologies will continue to be developed in the near future. Herein, the recent use of advanced materials used for developing COVID‐19 vaccines is summarized. John Wiley and Sons Inc. 2022-02-07 2022-03-24 /pmc/articles/PMC8957524/ /pubmed/34894000 http://dx.doi.org/10.1002/adma.202107781 Text en © 2022 Wiley‐VCH GmbH This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
spellingShingle Reviews
Mabrouk, Moustafa T.
Huang, Wei‐Chiao
Martinez‐Sobrido, Luis
Lovell, Jonathan F.
Advanced Materials for SARS‐CoV‐2 Vaccines
title Advanced Materials for SARS‐CoV‐2 Vaccines
title_full Advanced Materials for SARS‐CoV‐2 Vaccines
title_fullStr Advanced Materials for SARS‐CoV‐2 Vaccines
title_full_unstemmed Advanced Materials for SARS‐CoV‐2 Vaccines
title_short Advanced Materials for SARS‐CoV‐2 Vaccines
title_sort advanced materials for sars‐cov‐2 vaccines
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957524/
https://www.ncbi.nlm.nih.gov/pubmed/34894000
http://dx.doi.org/10.1002/adma.202107781
work_keys_str_mv AT mabroukmoustafat advancedmaterialsforsarscov2vaccines
AT huangweichiao advancedmaterialsforsarscov2vaccines
AT martinezsobridoluis advancedmaterialsforsarscov2vaccines
AT lovelljonathanf advancedmaterialsforsarscov2vaccines